Literature DB >> 19214674

Upper gastrointestinal ulcer in Japanese patients taking low-dose aspirin.

Akiko Shiotani1, Takashi Sakakibara, Yoshiyuki Yamanaka, Hiroshi Imamura, Ken-Ichi Tarumi, Noriaki Manabe, Tomoari Kamada, Hiroaki Kusunoki, Jiro Hata, Ken Haruma.   

Abstract

BACKGROUND: There are few studies on the association of the risks of upper gastrointestinal (GI) ulcer induced by aspirin combined with other medicines. We investigated the association between peptic ulcer and clinical parameters, including Helicobacter pylori infection and combinations of medicines.
METHODS: Patients taking 100 mg aspirin for cardiovascular diseases who were planning to undergo endoscopy were enrolled. Serum H. pylori IgG antibody was measured.
RESULTS: A total of 305 patients were enrolled, and 38 patients (12.4%) had ulcer lesions. Sex, smoking, drinking, body mass index, endoscopic findings for gastric atrophy (open type), or presence of H. pylori were not significantly associated with ulcer lesions. Cotreatment with anticoagulants [ticlopidine, 34.2% vs. 21.3%; adjusted odds ratio (OR), 3.1; 95% confidence interval (CI), 1.4-7.1; ticlopidine plus warfarin, 13.2% vs. 3.7%; adjusted OR, 4.4; 95% CI, 1.3-15], proton pump inhibitor (PPI 5.3% vs. 34.8%; adjusted OR, 0.10; 95% CI, 0.02-0.43), and antihypertensive medicine were significantly associated with peptic ulcer. Among antihypertensive medicines, AT1 receptor blocker and angiotensin-converting enzyme (ACE) inhibitor tended to be associated with upper GI ulcer.
CONCLUSIONS: PPI was superior to H2-receptor antagonist for prevention of peptic ulcer, and cotreatment with AT1 receptor blocker or ACE inhibitor seemed to reduce peptic ulcer among patients taking low-dose aspirin.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19214674     DOI: 10.1007/s00535-008-2290-6

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  41 in total

1.  Impaired platelet-connective-tissue reaction in man after aspirin ingestion.

Authors:  H J Weiss; L M Aledort
Journal:  Lancet       Date:  1967-09-02       Impact factor: 79.321

Review 2.  Collaborative overview of randomised trials of antiplatelet therapy--II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. Antiplatelet Trialists' Collaboration.

Authors: 
Journal:  BMJ       Date:  1994-01-15

3.  Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force.

Authors:  Michael Hayden; Michael Pignone; Christopher Phillips; Cynthia Mulrow
Journal:  Ann Intern Med       Date:  2002-01-15       Impact factor: 25.391

4.  Use of single and combined antithrombotic therapy and risk of serious upper gastrointestinal bleeding: population based case-control study.

Authors:  Jesper Hallas; Michael Dall; Alin Andries; Birthe Søgaard Andersen; Claus Aalykke; Jane Møller Hansen; Morten Andersen; Annmarie Touborg Lassen
Journal:  BMJ       Date:  2006-09-19

5.  Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. The Medical Research Council's General Practice Research Framework.

Authors: 
Journal:  Lancet       Date:  1998-01-24       Impact factor: 79.321

6.  Endoscopic characteristics and Helicobacter pylori infection in NSAID-associated gastric ulcer.

Authors:  Tomoari Kamada; Jiro Hata; Hiroaki Kusunoki; Kuniaki Sugiu; Tatsuro Tanimoto; Mitsuhiro Mihara; Hiroshige Hamada; Soichiro Kido; Qian Dongmei; Ken Haruma
Journal:  J Gastroenterol Hepatol       Date:  2006-01       Impact factor: 4.029

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  Benefits, morbidity, and mortality associated with long-term administration of oral anticoagulant therapy to patients with peripheral arterial bypass procedures: a prospective randomized study.

Authors:  Willard C Johnson; William O Williford
Journal:  J Vasc Surg       Date:  2002-03       Impact factor: 4.268

Review 9.  Pathogenesis and therapy of gastric and duodenal ulcer disease.

Authors:  Akiko Shiotani; David Y Graham
Journal:  Med Clin North Am       Date:  2002-11       Impact factor: 5.456

10.  Pentoxifylline prevents indomethacin induced acute gastric mucosal damage in rats: role of tumour necrosis factor alpha.

Authors:  L Santucci; S Fiorucci; M Giansanti; P M Brunori; F M Di Matteo; A Morelli
Journal:  Gut       Date:  1994-07       Impact factor: 23.059

View more
  21 in total

1.  Expression of angiotensin II type 1 and type 2 receptor mRNAs in the gastric mucosa of Helicobacter pylori-infected Mongolian gerbils.

Authors:  Mitsushige Sugimoto; Tomoyuki Ohno; Yoshio Yamaoka
Journal:  J Gastroenterol       Date:  2011-07-13       Impact factor: 7.527

2.  Combination of angiotensin II receptor blockers promotes proton pump inhibitor-based healing of reflux esophagitis.

Authors:  Hiroto Miwa; Michio Hongo; Motoyasu Kusano
Journal:  J Gastroenterol       Date:  2011-11-01       Impact factor: 7.527

3.  Hemorrhagic gastric and duodenal ulcers after the Great East Japan Earthquake Disaster.

Authors:  Kenichi Yamanaka; Hiroyuki Miyatani; Yukio Yoshida; Shinichi Asabe; Toru Yoshida; Misaki Nakano; Shin Obara; Hidehiko Endo
Journal:  World J Gastroenterol       Date:  2013-11-14       Impact factor: 5.742

4.  Gastric injury caused by low-dose aspirin therapy in consecutive Japanese patients: a prospective study.

Authors:  Shoji Fukuda; Shigeru Hosaka; Naomi Ozawa; Sam Akita; Toshitaka Kashima; Sosuke Kimura; Junichi Akiyama; Tetsuya Mizoue
Journal:  Gen Thorac Cardiovasc Surg       Date:  2012-03-28

5.  Biphasic effects of H. pylori infection on low-dose aspirin-induced gastropathy depending on the gastric acid secretion level.

Authors:  Katsunori Iijima; Nobuyuki Ara; Yasuhiko Abe; Tomoyuki Koike; Toshimitsu Iwabuchi; Hirohiko Shinkai; Kaname Uno; Hiroyuki Endo; Naoki Asano; Tooru Shimosegawa
Journal:  J Gastroenterol       Date:  2012-05-02       Impact factor: 7.527

6.  The preventive factors for aspirin-induced peptic ulcer: aspirin ulcer and corpus atrophy.

Authors:  Akiko Shiotani; Takashi Sakakibara; Yoshiyuki Yamanaka; Ryuji Nishi; Hiroshi Imamura; Minoru Fujita; Ken-ichi Tarumi; Tomoari Kamada; Jiro Hata; Ken Haruma
Journal:  J Gastroenterol       Date:  2009-05-16       Impact factor: 7.527

7.  Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide.

Authors:  Takatsugu Yamamoto; Akari Isono; Yuji Mishina; Tadahisa Ebato; Tsuguru Shirai; Shin Nakayama; Kunitaka Nagasawa; Koichiro Abe; Kengo Hattori; Taro Ishii; Yasushi Kuyama
Journal:  J Clin Biochem Nutr       Date:  2010-06-17       Impact factor: 3.114

8.  Primary non-variceal upper gastrointestinal bleeding in NSAID and low-dose aspirin users: development and validation of risk scores for either medication in two large Dutch cohorts.

Authors:  Nicolette L de Groot; Matthijs P Hagenaars; Hugo M Smeets; Ewout W Steyerberg; Peter D Siersema; Martijn G H van Oijen
Journal:  J Gastroenterol       Date:  2013-04-23       Impact factor: 7.527

Review 9.  Clinical features of gastroduodenal injury associated with long-term low-dose aspirin therapy.

Authors:  Junichi Iwamoto; Yoshifumi Saito; Akira Honda; Yasushi Matsuzaki
Journal:  World J Gastroenterol       Date:  2013-03-21       Impact factor: 5.742

10.  Effect of aspirin cessation before endoscopy in Japanese patients with low-dose-aspirin-associated gastroduodenal mucosal injury.

Authors:  Yoshitsugu Ito; Makoto Sasaki; Seiji Noguchi; Sumiharu Yamaguchi; Noriko Okaniwa; Atsushi Tanabe; Hisatsugu Noda; Kenichiro Yanamoto; Yasuhiro Tamura; Yoshihiro Kondo; Ryuta Masui; Shinya Izawa; Akihito Iida; Mari Mizuno; Naotaka Ogasawara; Yasushi Funaki; Kunio Kasugai
Journal:  United European Gastroenterol J       Date:  2013-08       Impact factor: 4.623

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.